CN111751551B - 蛋白分子作为诊断肝硬化的生物标志物及其预后方法 - Google Patents
蛋白分子作为诊断肝硬化的生物标志物及其预后方法 Download PDFInfo
- Publication number
- CN111751551B CN111751551B CN202010514476.2A CN202010514476A CN111751551B CN 111751551 B CN111751551 B CN 111751551B CN 202010514476 A CN202010514476 A CN 202010514476A CN 111751551 B CN111751551 B CN 111751551B
- Authority
- CN
- China
- Prior art keywords
- protein
- liver cirrhosis
- liver
- sample
- cirrhosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Engineering & Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010514476.2A CN111751551B (zh) | 2020-06-08 | 2020-06-08 | 蛋白分子作为诊断肝硬化的生物标志物及其预后方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010514476.2A CN111751551B (zh) | 2020-06-08 | 2020-06-08 | 蛋白分子作为诊断肝硬化的生物标志物及其预后方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111751551A CN111751551A (zh) | 2020-10-09 |
CN111751551B true CN111751551B (zh) | 2023-03-17 |
Family
ID=72674981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010514476.2A Active CN111751551B (zh) | 2020-06-08 | 2020-06-08 | 蛋白分子作为诊断肝硬化的生物标志物及其预后方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111751551B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112782297A (zh) * | 2020-12-24 | 2021-05-11 | 郭继生 | 一种肝硬化相关生物标志物及其筛选方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2430451A1 (en) * | 2009-05-14 | 2012-03-21 | The Chancellors, Masters and Scholars of the University of Oxford | Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers |
CN105992950A (zh) * | 2013-12-19 | 2016-10-05 | 欧普萨治疗股份有限公司 | T 细胞表位表达谱分析、制备 t 细胞组合物以及治疗疾病的方法 |
CN106405104A (zh) * | 2016-08-31 | 2017-02-15 | 鲁凤民 | 一种新的肝硬化或肝纤维化标志物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160041153A1 (en) * | 2008-11-12 | 2016-02-11 | Kirk Brown | Biomarker compositions and markers |
-
2020
- 2020-06-08 CN CN202010514476.2A patent/CN111751551B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2430451A1 (en) * | 2009-05-14 | 2012-03-21 | The Chancellors, Masters and Scholars of the University of Oxford | Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers |
CN105992950A (zh) * | 2013-12-19 | 2016-10-05 | 欧普萨治疗股份有限公司 | T 细胞表位表达谱分析、制备 t 细胞组合物以及治疗疾病的方法 |
CN106405104A (zh) * | 2016-08-31 | 2017-02-15 | 鲁凤民 | 一种新的肝硬化或肝纤维化标志物 |
Non-Patent Citations (2)
Title |
---|
Growth arrest and DNA damage-inducible 45α protects against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet;Naoki Tanaka 等;《Biochimica et Biophysica Acta-Molecular Basis of Disease》;20170824;第1863卷(第12期);第3170-3182页 * |
HEPATOCELLULAR CARCINOMA: NOVEL MOLECULAR APPROACHES FOR DIAGNOSIS, PROGNOSIS AND THERAPY;Augusto Villanueva M D 等;《Annu Rev Med》;20130610;第61卷;第317-328页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111751551A (zh) | 2020-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102027373B (zh) | 发现用于前列腺癌诊断和治疗之生物标志物和药物靶标的方法及其确立的生物标志物测定 | |
Yu et al. | Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification | |
AU2007230967A1 (en) | Apolipoprotein fingerprinting technique | |
CN107110867A (zh) | 用于肝癌诊断的生物标记物及其用途 | |
CN112071363B (zh) | 胃黏膜病变蛋白质分子分型、病变进展及胃癌相关蛋白标志物、预测病变进展风险的方法 | |
US20160363560A9 (en) | Metabolite Biomarkers for the Detection of Esophageal Cancer Using NMR | |
Wessels et al. | Plasma glycoproteomics delivers high-specificity disease biomarkers by detecting site-specific glycosylation abnormalities | |
CN111751551B (zh) | 蛋白分子作为诊断肝硬化的生物标志物及其预后方法 | |
CN116879558B (zh) | 卵巢癌诊断标志物、检测试剂及检测试剂盒 | |
CN105699473A (zh) | 胃癌唾液蛋白指纹图谱分子诊断模型建立方法 | |
CN111748623B (zh) | 肝癌患者是否复发的预测标志物及试剂盒 | |
CN117686712A (zh) | 一种基于舌苔微生物蛋白筛查胃癌的方法 | |
Song et al. | MALDI‐TOF‐MS analysis in low molecular weight serum peptidome biomarkers for NSCLC | |
CN111748624B (zh) | 用于预测肝癌是否复发的生物标志物 | |
CN116148482A (zh) | 用于乳腺癌患者鉴定的设备及其制备用途 | |
CN115128285B (zh) | 一种蛋白质组合对甲状腺滤泡性肿瘤鉴别评估的试剂盒、系统 | |
Liao et al. | Serum profiling based on fucosylated glycoproteins for differentiating between chronic hepatitis B and hepatocellular carcinoma | |
CN107003371A (zh) | 用于确定主体患胰腺癌的可能性的方法 | |
WO2010030641A2 (en) | Pancreatic cancer markers | |
CN111751550B (zh) | 肝癌诊断的生物标志物及其预后方法 | |
CN113125757A (zh) | 一种用于母猪早期妊娠诊断的蛋白生物标志物及其用于母猪早期妊娠诊断方法 | |
CN111751549A (zh) | 蛋白分子在肝癌诊断中的预后方法及其应用 | |
CN109870580B (zh) | 血清蛋白标志物组在制备鉴别血吸虫病检测试剂盒中的应用及检测试剂盒 | |
CN108828229B (zh) | 食管癌肿瘤标志物组合及其应用 | |
CN112379095A (zh) | 一种2型糖尿病患者肺腺癌诊断标志物pzp及其elisa试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230403 Address after: Room 102, Management Office, Floor 1, Building 3, the Taihu Lake New Town Science and Technology Innovation Park, No. 18, Suzhou River Road, East the Taihu Lake Ecological Tourism Resort (the Taihu Lake New Town), Wujiang District, Suzhou City, Jiangsu Province, 215200 Patentee after: Suzhou Nuofeng Biotechnology Co.,Ltd. Address before: 450000 East Construction Road No. 50, Erqi District, Zhengzhou City, Henan Province Patentee before: THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230703 Address after: Room 102, Management Office, Floor 1, Building 3, the Taihu Lake New Town Science and Technology Innovation Park, No. 18, Suzhou River Road, East the Taihu Lake Ecological Tourism Resort (the Taihu Lake New Town), Wujiang District, Suzhou City, Jiangsu Province, 215200 Patentee after: Phoenix Intelligent Pharmaceutical Biotechnology (Suzhou) Co.,Ltd. Address before: Room 102, Management Office, Floor 1, Building 3, the Taihu Lake New Town Science and Technology Innovation Park, No. 18, Suzhou River Road, East the Taihu Lake Ecological Tourism Resort (the Taihu Lake New Town), Wujiang District, Suzhou City, Jiangsu Province, 215200 Patentee before: Suzhou Nuofeng Biotechnology Co.,Ltd. |